Moteur de recherche d’entreprises européennes
Financement de l’UE (4 220 732 €) : De minuscules machines travaillant à élucider les mécanismes des pathologies cérébrovasculaires Hor14/07/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
De minuscules machines travaillant à élucider les mécanismes des pathologies cérébrovasculaires
The CerebroMachinesTrain Doctoral Network (CMT-DN) seeks to go beyond the state-of-the-art of drug delivery systems by focusing on tiny machines (TMs) that can be engineered as stable formulation devices capable of: i) transporting the desired amount of therapeutic substance (drug) to a target area; ii) preserving its designed function under variable physiological parameters; iii) enhancing drug bioavailability; iv) preserving the healthy environment (cells, tissues, organs) with minimal to no side effects. These TMs will require innovative engineering designs to face the complex brain environment in which they must perform as a first organ testing platform. CMT-DN aims to train and transform a young, talented generation of 14 researchers to PhD level and as future leaders in the state-of-the-art engineering of TMs and brain-on-chip devices (VRAINORG) for unravelling the mechanisms and improved treatment options underlying cerebrovascular pathologies. The engineered TMs will be designed to work and tested against VRAINORG platforms, which are 3D non-animal technologies of vascularised brain organoids (healthy and disease models) incorporated within microphysiological systems (MPs). This innovative training programme will bring together a panel of academic and industry experts in TMs biomimetic therapeutic systems and brain MPs comprising five academic and four industry partner beneficiaries, consolidated through three academic and two industry-associated partners covering nine countries across Europe and beyond, including one US associated partner. By employing these emerging non-animal technologies (i.e., vascularised brain-on-chip models), the resulting innovative therapeutic systems will benefit from facilitated clinical translation while reducing the high cost and time-consuming aspects of pre-clinical animal studies.
| AxoSim Technologies LLC | ? |
| Basque Center For Macromolecular Design And Engineering Polymat Fundazioa | 564 376 € |
| IBIDI GmbH | 290 272 € |
| Institutul de Chimie Macromoleculara Petru Poni | 246 243 € |
| Microfluidics Innovation Center | 314 669 € |
| MIMETAS B.V. | 305 286 € |
| React4Life S.p.A. | 281 755 € |
| TECHNISCHE UNIVERSITAT DARMSTADT | 290 272 € |
| Universita Degli Studi Di Trento | 563 510 € |
| University of Galway | 1 364 348 € |
https://cordis.europa.eu/project/id/101227628
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : AxoSim Technologies LLC, New Orleans, États-Unis.
